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PENILAIAN HASIL KEMOTERAPI DAN PENGURUSAN PERISTIWA ADVERS 
DI KALANGAN PESAKIT KANSER PEPEJAL HOSPITAL PULAU PINANG 
 
ABSTRAK 
Dalam abad ini, kanser telah menjadi salah satu masalah dan penyakit utama 
yang telah menyebabkan banyak kematian  dan akan melebehi penyakit jantung. 
Penyakit kanser dan rawatan kemoterapi mempunyai banyak kesan sampingan yang 
berbahaya yang boleh menjejaskan kualiti hidup (QOL) pesakit-pesakit kanser. 
Oleh itu kajian ini dilakukan untuk mengesan faktor-faktor risiko utama 
berkaitan dengan loya dan muntah, anemia, trombositopenia dan hiperkalsemia dan 
untuk menilai keberkesanan garis panduan rawatan masing-masing. Di samping itu 
QOL pesakit kanser payudara yang mengalami loya dan muntah juga dinilai. Kajian 
prospektif dan retrospektif  telah dijalankan keatas pesakit-pesakit kanser pepejal 
yang dimasukkan ke Hospital Pulau Pinang. Data telah dikumpulkan dengan 
menggunakan kaedah temuduga secara bersemuka untuk bahagian prospektif (loya 
dan muntah-muntah) dan dengan menggunakan lembaran data khusus untuk 
bahagian retrospektif (anemia, trombositopenia dan hiperkalsemia). Maklumat telah 
dikumpul daripada fail-fail pesakit yang disimpan di klinik onkologi dan pejabat 
rekod hospital. 
Kajian prospektif tertumpu terhadap faktor-faktor risiko dan QOL pesakit kanser 
payudara (n=158) yang mengalami loya dan muntah setelah rawatan kemoterapi. Faktor-
faktor risiko ini termasuk data demografik pesakit, maklumat kanser payudara, data 
kemoterapi, data ciri-ciri pesakit dan rawatan loya dan muntah.  Faktor-faktor utama 
berkaitan dengan loya dan muntah aruhan kemoterapi (CINV)  tertangguh dan akut ialah 
etnik pesakit, kitaran dan jenis kemoterapi  serta  rawatan pra dan pasca antiemetik yang 
digunakan.  CINV  tertangguh mempunyai kesan negatif terhadap QOL pesakit kanser 
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payudara yang lebeh besar berbanding kesan CINV akut. Di samping itu, kajian 
menunjukkan bahawa terdapat kepincangan dalam garis panduan rawatan antiemetik  yang 
mungkin disebabkan oleh perbezaan etnik dikalangan pelbagai bangsa. 
Bahagian kedua adalah  kajian retrospektif observasional  ke atas pesakit kanser 
yang dimasukkan ke hospital di antara tahun 2003 dan 2009 yang mengalami anemia atau 
trombositopenia atau hiperkalsemia.  Menurut kajian ini, faktor risiko  utama berkaitan 
dengan anemia, trombositopenia dan hiperkalsemia adalah jenis dan tahap penyakit kanser; 
jenis kemoterapi; skedul kemoterapi, kitaran kemoterapi dan dos (tinggi) kemoterapi serta 
rawatan. Satu lagi  hasil kajian penting  yang diperolehi berkaitan dengan anemia (n=534 
pesakit) ialah garis panduan rawatan yang digunakan adalah tidak cukup berkesan dan hanya 
bersifat sementara. Hasil kajian yang sama turut diperolehi untuk trombositopenia (n=341 
pesakit) dan hiperkalsemia (n=292 pesakit), menunjukkan garis panduan rawatan tidak 
berkesan. Oleh yang demikian, garis panduan rawatan dan cadangan-cadangan baru digubal 
berdasarkan daripada hasil kajian ini.  
Katakunci: Loya dan Muntah, Loya dan Muntah Tertangguh, Loya dan Muntah Akut, QOL, 
Anemia, Trombositopenia, Hiperkalsemia, Garis Panduan Rawatan. 
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ASSESSMENT OF CHEMOTHERAPY OUTCOME AND ADVERSE EVENT 
MANAGEMENT AMONG SOLID CANCER PATIENTS OF PENANG HOSPITAL 
 
ABSTRACT 
 During this century, cancer has become one of the major problem and diseases 
which has caused predominant death and will even surpass heart diseases. Both cancer 
diseases and chemotherapy have many hazardous side effects which could also affect the 
quality of life (QOL) of cancer patients. 
Thus this study was performed to detect the main risk factors associated with nausea 
and vomiting, anemia, thrombocytopenia and hypercalcemia and to evaluate effectiveness of 
respective treatment guidelines. In addition QOL of breast cancer patients with nausea and 
vomiting was also evaluated. Prospective and retrospective studies were conducted on solid 
cancer patients admitted to Penang, Hospital. Data were collected by using direct person-to-
person interview for the prospective part (nausea and vomiting) and by using specific data 
sheet for the retrospective part (anemia, thrombocytopenia and hypercalcemia).  The 
required data were collected from patients’ files kept in the oncology clinic and the record 
office of the hospital. 
The prospective study focused on risk factors and QOL of breast cancer patients 
(n=158) suffering from nausea and vomiting after chemotherapy administration. These risk 
factors include patient's demographic data, breast cancer information, chemotherapy data, 
patients’ characteristic data and treatment of nausea and vomiting. The main risk factors 
associated with delayed and acute chemotherapy induced nausea and vomiting (CINV) are 
patients ethnicity, chemotherapy cycles and types, as well as pre and post antiemetic 
treatments used. As for the effect on QOL, delayed CINV has a higher negative effect on 
breast cancer patients QOL than acute CINV.  Moreover it shows that there is a defect in the 
antiemetic treatment guideline which might be due to ethnic variation among the different 
races.  
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The second part is an observational retrospective study among solid cancer patients 
admitted between 2003 and 2009 who developed anemia or thrombocytopenia or 
hypercalcemia. According to this study, the main risk factors associated with anemia, 
thrombocytopenia and hypercalcemia are types and stages of solid cancer disease, 
chemotherapy type, chemotherapy schedule, chemotherapy cycle, and chemotherapy dose 
(high) as well as the treatment.  Other important result related to anemia (n=534 patients) is 
that the treatment guidelines employed is not effective enough and was only temporary. 
Similar findings were obtained with thrombocytopenia (n= 341 patients) and hypercalcemia 
(n= 292 patients), indicating ineffectiveness of treatment guideline. Thus new treatment 
guidelines and recommendations are developed based on the findings. 
Keywords: Nausea and Vomiting, Acute Nausea and Vomiting , Delayed Nausea and 
Vomiting, QOL, Anemia, Thrombocytopenia, Hypercalcemia, Treatment Guidelines. 
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CHAPTER 1  
INTRODUCTION 
 
1.1 Cancer Background  
          During this century, cancer has become one of the major problem and diseases which 
has caused predominant death and it will even surpass heart diseases. Many of the 
researchers begin to use the term lifetime risk for cancer patients which refer to the time that 
cancer will progress and developed or the time that the patient will die because of cancer. 
Cancer does not represents only one disease but it is a group involving about 100 diseases. 
Cancer is characterized by two things. Firstly there is no control for the growth of cancer 
cells and secondly is the ability of the cancer cells to metastasis and migrate from the 
original site to different parts of the body. There are two types of tumors which are 
malignant and benign cancer. Cancer can attack any person and its occurrence increases as 
the age of the individual increase too (Carson-De Witt, 2002; Markman, 2002). There are 
many problems (i.e., side effects) associated with cancer diseases either solid or 
hematological cancer such as nausea, vomiting, diarrhea, constipation, hypercalcemia, pain, 
lost of appetite, anemia, fatigue, cachexia, leucopenia, neutropenia and thrombocytopenia. 
However the major problems are nausea and vomiting, neutropenia, anemia, 
thrombocytopenia and hypercalcemia. Hence due to these reasons cancer is considered as 
one of the major diseases that will effect the quality of life (Dolan, 2005; Henry, 2005; 
Sitamvaram, 2005; Stephens, 2005).  
         
1.2 Chemotherapy Background  
 Chemotherapy was developed and used since the Word War I from the chemical 
weapon program of the United State of America (USA). Since then chemotherapy has 
became as one of the most important and significant treatment of cancer. Its main 
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mechanism of action is by killing the cancer cells which are characterized by their high 
multiplication and growth rate. It will also kill all the cancer cells that had broken off from 
the main tumor and spread to the blood or lymphatic system or any part of the body. This 
killing process of cells is either by a direct effect on deoxyribonucleic acid (DNA) or an 
effect on the factors involved in mitosis by inhibition of its synthesis or production or uses 
(Weir-Hughes, 2005; Scurr et al., 2005; Kelland, 2005). Chemotherapy drug may lead to 
complete cure for some types of cancers or may suppress the growth of others or may 
prevent their spread to other parts of the body. So many types of new therapies have emerged 
over the past 20 years. Some of them were straight forward, effective and safe and some 
have many side effects. However when comparing chemotherapy with other types of 
treatments, it still remain potentially high risk with many side effects which are difficult to 
manage. Chemotherapy used required the involvement of various clinical professionals 
during its various stages of administration and enormous patient health care is needed to 
overcome its side effects (Weir-Hughes, 2005; Rizzo and Closs, 2002). 
 
1.3    Chemotherapy Side Effects 
The goal of chemotherapy is to be as effective as possible with tolerable side effects, 
since the dose of chemotherapy will be toxic to the cancer cells as well as to the normal cells. 
A proportion of the cancer patients suffer from only mild side effects whereas others may 
suffer from serious side effects (Abrams, 2001; Koda-Kimble et al., 2002; Rizzo and Cloos, 
2002). These side effects are classified as: 
1- Acute, which develop within 24 hours after chemotherapy administration.  
2- Delayed, which developed after 24 hours and up to 6 to 8 weeks after chemotherapy 
treatments. 
3- Short term, combination of both acute and delayed effect. 
4-  Late/ long term, which developed after months or years of chemotherapy treatment. 
5- Expected, which developed among 75% of the patients. 
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6- Common, occurred in 25%-75% of the patients. 
7- Uncommon, happened is less than 15% of the patients. 
8- Rare, occur in only 5% of the patients. 
9- Very rare, occur with less than 1% of the patients (Abrams, 2001; Koda-Kimble et 
al., 2002; Rizzo and Cloos, 2002). 
 Occurrence of specific side effects will vary according to the chemotherapy used. The most 
common side effects experienced are nausea and vomiting, anemia, hair lost, bleeding, 
thrombocytopenia, hyperuricemia, bone marrow depression, alopecia and mucositis. So 
different parameters must be taken into consideration to prevent, reduce and overcome these 
side effects (Abrams, 2001; Koda-Kimble et al., 2002; Rizzo and Cloos, 2002).  
 
1.4 Main Problems Caused by Solid Cancer Diseases and Chemotherapy   
1.4.1    Nausea and Vomiting 
Both nausea and vomiting are recognized as two separate and distinct conditions. 
Nausea is an unpleasant sensation of being vomit or urge to vomit which may or may not 
result in vomiting. While, vomiting or emesis is the process of expelling of digested and 
undigested food through the mouth. Nausea and vomiting can arises from a different or wide 
spectrum of etiologies which are either directly associated to cancer disease itself or its 
treatment. According to the new ranking of chemotherapy side effects, nausea is the number 
one or the most disturbing side effect, followed by fatigue, neutropenia, anemia or 
thrombocytopenia, hair losing while vomiting is the third and sometimes the fifth disturbing 
chemotherapy side effects. Even so, not all cancer patients suffer from nausea and/ or 
vomiting because not all of them were treated with emetogenic chemotherapy (Haggert, 
1999; Oberleitner, 2002; Coates et al., 1983; Lebourgeois et al., 1999; Morrow et al., 2005; 
Hesketh, 2005; Rudd and Andrews, 2005).  
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1.4.1.1       Causes of Nausea and Vomiting 
          There are several factors involved in the stimulation of nausea and vomiting and these 
factors included stress, pregnancy, motion sickness, migraine headache, cancer stages, radio 
therapy and chemotherapy.  
The main focus of this part of the study will be on the factors causing nausea and vomiting 
related with solid cancers specifically breast cancer and chemotherapy. Nausea and vomiting 
is one of the major problems that is associated with cancer patients and 50%-55% of cancer 
patients suffer from both nausea and vomiting even with the use of antiemetic drugs. The 
main causes for this are either due to the chemotherapy or because of the cancer progression. 
Some of the cancer patients who were treated with chemotherapy did not suffer from nausea 
or vomiting because the chemotherapy used were not significantly emetogenic. Nausea and 
vomiting still remain the major side effects that occur and is associated with chemotherapy 
and cancer diseases (Haggerty, 1999; Oberleitner, 2002; Mitchell and Schein, 1984; Bartlett 
and Koczwara, 2002).  
1.4.1.2 Nausea and Vomiting in Solid Cancer Patients  
          Both nausea and vomiting are very common problems especially with advanced stages 
of solid cancer diseases like breast cancer and stomach cancer where 50 to 60% of the 
patients are mainly female under 65 years of age (Molassiotis and Böjeson, 2006). In this 
situation, nausea and vomiting occur because of the advanced stages of solid cancer diseases 
characterized by more severe complications than that caused by chemoradiotherapy or other 
treatments. The main causes for those problems are gastric stasis, obstruction of the intestine, 
opioid use, constipation caused by morphine uses, hypercalcemia, brain metastasis, renal 
failure, hyponatremia, increases in the intracranial pressure and tumor burden (Molassiotis 
and Böjeson, 2006). With regards to solid tumor burden, breast cancer causes nausea and 
vomiting especially at its advance stages is by metastasis to the abdomen (mainly stomach or 
liver) or central nervous system (CNS). So emphasis on the details of the effect of advance 
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stages of cancer on nausea and vomiting should be made which up to now was given only 
little attention (Molassiotis and Böjeson, 2006).  
 
1.4.1.3     Pathophysiology of Chemotherapy-Induced Nausea and Vomiting   
          Chemotherapy cause nausea by stimulating the autonomic nervous system (ANS), 
while vomiting is triggered when afferent impulses from chemoreceptor trigger zone (CTZ), 
pharynx, cerebral cortex and vagal afferent fiber stimulate the vomiting center (VC) located 
in the medulla. The stimulation of the VC leads to contraction of muscles of abdomen, chest 
wall and diaphragm, so this will lead to an expulsion of stomach and intestine contents 
(Haggerty, 1999; Oberleitner, 2002; Mitchell and Schein, 1984; Bartlett and Koczwara, 
2002; Navari, 2007). Nausea and vomiting associated with surgery, chemotherapeutic 
agents, radiotherapy and pregnancy are thought to be induced by stimulating the dopamine-2 
(D2), acetylcholine, histamine, and serotonin-3 (5-HT3) neuro-receptors involved in 
activating specific areas of the brain that coordinate the act of vomiting (Beckley, 2005). 
Also some studies have reported the involvement of neurokinin receptors (NK-1) especially 
in delayed emesis, while histamine and muscarinic receptors have lesser role in emesis 
associated with motion sickness (Hesketh et al., 2003; Grunberg and Hesketh, 1993). The 
main mechanism of chemotherapy induced vomiting is the stimulation of the 
entrochromaffin cells lining the wall of the gastrointestinal tract (GIT) hence causes the 
release of the serotonin. The serotonin will then bind to the vagal afferent 5-HT3 receptors in 
the GIT which will send impulses to the CTZ and VC. This is illustrated in Figure 1.1.  
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Figure 1.1 Responsible Neurotransmission Pathways for Chemotherapy Induce Nausea 
and Vomiting (CINV) (ASHP, 1999).  
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1.4.1.4     Major Patients Risk Factors Associated with Incidence and        
    Severity of Nausea and Vomiting 
 
Direct factors associated are: gender, age, history of motion sickness, history of 
vomiting during pregnancy, history of alcohol consumption and patient anxiety (Haggerty, 
1999; Oberleitner, 2002; Hesketh, 2001; Osoba et al., 1997; Hesketh, 2005; Rubenstein, 
2005). 
 When comparing between men and women, women have 2-3 fold higher chance of emesis 
or need for use of antiemetic prophylaxis treatment within the first 24 hours after receiving 
high dose of highly emetogenic chemotherapy. While in case of moderate emetogenic 
chemotherapy drugs, women have significantly lower response rate than men to 5-HT3 
antagonist either when it given as single or combination treatment with dexamethasone, for 
prevention or protection against emesis or freedom from nausea within the first 24 hours 
after chemotherapy administration. Other serious and important risk factor is the age, where 
by younger cancer patients are characterized by poor response to the antiemetic prophylaxis. 
When comparing the cancer patients according to their ages the results showed that higher 
percentage of the younger patients suffered from nausea and vomiting than older patients. In 
some studies the patients were grouped into those more than 55 years old and those less than 
55 years old. In these studies the results showed that all patients more than the mean age of 
the study population showed lower risk of nausea and emesis with the chemotherapy. Also 
patients who suffered from nausea and vomiting of other etiologies are more susceptible to 
nausea and vomiting due to chemotherapy treatment. Emesis during pregnancy is consider as 
one of the risk factor for chemotherapy induce nausea and vomiting (CINV) but the evidence 
for it is still limited. Alcohol consumption has been indicated as one of protective factors 
against progress of CINV, however many factors are associated with alcohol consumption 
and thus this is still not clear whether heavy alcohol consumption (> 100 g/ day) is a 
protective factor itself or it will cause genetic change leading to protection from emesis. 
Some authors think that the chronic consumption of alcohol lead to lower sensitivity of 
chemoreceptor trigger zone to emetic stimuli (Hesketh, 2005). Patient anxiety is a predictive 
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factor for occurrence and development of delayed and anticipatory emesis. This is because 
anxiety stimulate the forebrain areas (cortex and limbic system) thus reduce the threshold 
which will make other inputs induce emesis easily (Hesketh, 2005).                                    
1.4.1.5    Major Chemotherapy Factors Responsible For Incidence and Severity of 
Nausea and Vomiting 
         There are several chemotherapeutics factors that play major role in the incidence and 
severity of both nausea and vomiting which are: 
1- Emetogenic potential of the drug 
2- Dosage level  
3- Schedule of administration  
4- Route of administration 
5- History of previous chemotherapy 
6- Rate of I.V infusion (Haggerty, 1999; Oberleitner, 2002; Hesketh, 2001; Hesketh, 
2005; Ballatori and Roila, 2005).  
According to the emetogenic potential, chemotherapy drugs are classified as severe, high, 
moderate, low and very low depending on the percentage of the cancer patients developing 
nausea and vomiting. Even with the low emetogenic potential chemotherapeutics drugs, 
there is still the chance of inducing nausea and vomiting when high doses are given. Another 
example whereby the emetogenic potential is affected by chemotherapy doses is with 
cisplatin. Cisplatin dose higher than 50mg/ m2 will lead to 100% occurrence of emesis if 
antiemetic prophylaxis is not given. Cyclophosphamide is a moderate emetogenic drug when 
the dose used is between 500-750 mg/ m2 but is a highly emetogenic drug when the dose is 
higher than 1500 mg/ m2 (Haggerty, 1999; Oberleitner, 2002; Hesketh, 2001; Hesketh, 2005; 
Ballatori and Roila, 2005). Schedule of administration especially when various drugs are 
administrated together, will also lead to significant implications for clinical action and 
toxicity, which i.e., either increases or decreases toxicity or efficacy. This is because this 
schedule will have an effect on the pharmacokinetic, biochemical and cell related 
interactions example when cisplatin administration precedes paclitaxel, it will cause 
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antagonism in their action, while when sequence is inversed this will lead to synergistic 
effect and will lead to increase in the toxicity of the two drugs i.e., increases in their 
myelotoxicity, nausea and vomiting effect and other side effects. These are due to the 
pharmacokinetic interactions of both drugs (Haggerty, 1999; Oberleitner, 2002; Hesketh, 
2001; Hesketh, 2005; Ballatori and Roila, 2005).  
It is very important that there must be good control on emesis from the first cycle of the 
chemotherapy. This is because patients who experienced emesis with early stages of 
chemotherapy treatment will have poor response toward antiemetic treatments in the later 
cycles. Also response to the antiemetic prophylaxis will gradually decline over time with 
chemotherapy cycles and about 30% of the patients will develop emesis at the fourth cycle of 
chemotherapy. Rate of chemotherapy administration is another important factor related with 
incidence of emesis. This is seen with doxorubicin which is a moderate emetogenic agent, 
but became less emetogenic when given by continuous infusion and became highly 
emetogenic when given in more rapid rate of bolus dose (Haggerty, 1999; Oberleitner, 2002; 
Hesketh, 2001; Hesketh, 2005; Ballatori and Roila, 2005; Scurr et al., 2005).  
 
1.4.1.6     Classification of Chemotherapy Induced Nausea and Vomiting         
 This classification is based on the emetogenic potential of the chemotherapeutic drug. 
1- Severe (90% of the patients will experience nausea and vomiting) Example: 
Cisplatin I.V ≥ 50 mg/ m2, Cyclophosphamide I.V > 1500 mg/ m2 and Dacarbazine.    
2- High (60%-90%) Example: Carboplatin, Cisplatin I.V < 50 mg/ m2, 
Cyclophosphamide I.V 750 mg/ m2 to 1500 mg/ m2 and Cytarabine I.V > 1gm/ m2. 
3- Moderate (30%-60%) Example: Altretamine I.V PO dose, Asparginase, 
Cyclophosphamide (I.V) ≤ 750 mg/ m2, Cyclophosphamide PO dose, Doxorubicin 
(I.V) 20 to 60 mg/ m2, and Ifosfamide.   
4- Low (10%-30%) Example: Capecitabine PO dose, Docetaxel, Doxorubicin 
liposomal, Fluorouracil and Gemcitabine.     
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5-    Very low (less than 10%) Example: Bleomycin, Busulfan PO dose, Methotrexate < 
50mg/ m2 (Hesketh, 2000; Rubenstein, 2005).  
 
1.4.1.7     Diagnosis of Incidence of Nausea and Vomiting  
 The diagnosis of nausea and vomiting is based on different parameters mainly 
severity, frequency of occurrence and duration of symptoms associated with nausea and 
vomiting (Haggerty, 1999; Oberleitner, 2002).  
 
1.4.1.8     Classification and Incidence of Chemotherapy Induced Nausea and   
                 Vomiting  
  
 CINV are clinically classified as: 
1-  Acute chemotherapy related nausea and vomiting 
2-  Delayed emesis 
3-  Anticipatory emesis (Hesketh, 2005; KRIS et al., 1985; Haggerty, 1999; Oberleitner, 
2002).  
 Acute emesis is defined as nausea and/ or vomiting or both that occurred within the 
first 24 hours after chemotherapy administration. It has very important characteristic which 
is the arbitrary time frame of 24 hours and according to this emesis most commonly occur 
within one to two hours. The peak of the emesis is within four to six hours and after which 
emesis will start to subside.  
 Delayed emesis include nausea and/ or vomiting happening after 24 hours of 
chemotherapy administration. Delayed emesis is best characterized by cisplatin 
administration whereby the emesis peaks within four to six hours and then subsides within 
the next 12 to 16 hours i.e., the acute phase. Then after 24 hours of quiescent period emesis 
will become obvious again, reaching its peak within 48 to 72 hours and this is the delayed 
phase. Usually this type of delayed emesis is less intensive than acute emesis and will 
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resolved in the next two to three days. Many chemotherapy other than cisplatin such as 
carboplatin, anthracyclines and cyclophosphamide can cause delayed emesis.  
 Anticipatory emesis happens in patients who already suffered from acute and delayed 
emesis during the previous cycles. There are many causes and factors which can cause 
anticipatory emesis prior to chemotherapy cycles. However if acute and delayed emesis are 
well controlled, anticipatory emesis within the next few years became a much less significant 
problem (Hesketh, 2005; Oberleitner, 2002).  
1.4.1.9     Grading of Nausea and Vomiting Severity for Acute and Delayed Phase 
Several numerical grading have been used to clarify the severity of nausea and 
vomiting as shown in Table 1. 
 
  Table 1.1: Grading of Chemotherapy Induced Nausea and Vomiting Severity for  
                  Both Acute and Delayed    
     
  (Cancer therapy evaluation program VERSION 3.0, 2008). 
 
Grade of 
severity 
Grade 1 Grade 2 Grade 3 Grade 4 Grade5 
Nausea  Loss of 
appetite 
without alter 
in eating 
habit 
Oral intake 
decreases 
without 
significant  
weight loss, 
dehydration 
I.V fluids 
given < 24 hr 
Inadequate 
oral fluids 
and calories 
intake, on 
I.V fluids, 
tube feeding 
or on TPN 
≥24 hr  
Life 
threatening 
consequences  
Death 
Vomiting 1 episode in 
24 hours  
2-5 episodes 
in 24 hr; I.V 
fluids 
indicated < 
24 hr 
≥6 episodes 
in 24 h; IV 
fluids, or 
TPN 
indicated 
≥24 h 
Life-
threatening 
consequences 
Death  
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1.4.1.10     Association of Acute Emesis with Delayed Emesis 
 Nausea and vomiting are not independent phenomena, they are both strictly correlated 
with each other in both acute and delayed phase. It has been found that delayed emesis is 
mainly dependent on acute episode so when emesis happens in the first cycle of 
chemotherapy administration (acute phase) then it will be absolutely observed in the delayed 
phase. Many studies have shown that patients with good protection against emesis during the 
first cycle of chemotherapy (acute phase) will show a low probability of delayed emesis with 
subsequent cycles (Ballatori and Roila, 2005). Incidence of delayed emesis is in the range of 
50% to 90% in those patients who have poor control of emesis in their early chemotherapy 
cycles, as compare to about 10% to 50% in those who have good control of emesis in their 
early cycles (Rubenstein, 2005).  
1.4.1.11     Nausea and Vomiting Treatment  
 The main goal of the antiemetic treatment is to abolish nausea and vomiting which in 
the last twenty years is consider as an inevitable chemotherapy side effects. This prevention 
is focused on the entire period of emetic risk which is 4 days for patients who received 
highly or moderately emetogenic chemotherapy (Navari, 2007; Jordan et al., 2005). This 
could be perfectly achieved by understanding the mechanisms of these antiemetic drugs 
either alone or in combination so as to get their maximum benefit (Grunberg and Dugan, 
2005).  Modern antiemetic treatments help in preventing 70%-80% of nausea and vomiting 
problems. Combination antiemetic treatment becomes the standard regimen used for the 
control of nausea and vomiting caused by chemotherapy (Grunberg and Dugan, 2005). The 
different types of treatments are as follows:  
1-  Serotonin-receptor antagonists (5-HT3) 
2-  Dopamine-2-receptor antagonists  
3-  Corticosteroids 
4-  Neurokinin-1-recptor antagonists  
5-  Cannabinoids 
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6-  Benzodiazepines (Jordan et al., 2005).  
1.4.1.11.1    Serotonin-Receptor Antagonists (5-HT3) 
 These agents are one of the most effective antiemetic treatment for acute nausea and 
vomiting caused by chemotherapy, even for the acute nausea and vomiting resulting from 
highly emetogenic chemotherapy like cisplatin. They selectively block the 5-HT3 receptor in 
the periphery (visceral vagal afferent fiber) and in the brain (CTZ) (Jordan et al., 2005; 
Oberleitner, 2002; Haggerty, 1999). These agents have specific characteristics as described 
below: 
1-  The lowest effective dose should be used because high doses will lead to saturation of 
receptors and will not lead to any enhancement in the antiemetic activity. 
2-  Both oral and intravenous route will give similar action. 
3-  Single dose is as effective as multiply doses regimens. 
4-  The adverse effects of these agents are acceptable (Jordan et al., 2005).    
The 5-HT3 antagonist drugs most commonly used are dolasetron (Anzemet®), granisetron ( 
Kytril®) and ondansetron (Zofran®). These three drugs are found to be similar in their effect 
and side effect. Both ondansetron and granisetron can prevent 50%-60% of the emesis 
caused by the highly emetogenic chemotherapy (i.e., cisplatin). The effective dose for this 
are dolasetron (I.V= 1.8 mg/ kg, oral= 100 mg, PO= 100 mg), ondansetron (I.V= 0.15 mg/ 
kg or 8-24 mg, PO= 12-24 mg) and granisetron (I.V= 0.01 mg/ kg or 1 mg, PO= 2mg) (Kris 
et al., 1985; De Mulder et al., 1990; Hesketh et al., 1996; Cubbedu et al., 1990; Navari et al., 
1995; Howland and Mycek, 2006).  
1.4.1.11.2     Dopamine-2- Receptor Antagonists 
 These agents were the main agents for antiemetic therapy from 1950s until 1980s. 
However, their efficacy as single agents is low compared with other agents. These agents 
produce their antiemetic effect through blocking of the dopamine receptors in the CTZ and 
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VC. This antiemetic class is divided into butyrophenones (e.g., droperidol and haloperidol), 
phenothiazines (e.g., prochlorperazine) and substituted benzamides (e.g., metoclopramide). 
conventional dose of metoclopramide is effective in treating with emesis due to mild to 
moderate emetogenic chemotherapy. While in case of highly emetogenic chemotherapy like 
cisplatin, metoclopramide need to be given in high doses so it will produce its antiemetic 
effect by antagonism at the 5HT3 receptors. The high doses for metoclopramide is 1-2 mg/ 
kg which can be given for 6-8 times per day to a maximum dose of 12 mg/ day. The adverse 
effects especially when receiving high doses of these agents include orthostatic hypotension, 
extrapyramidal symptoms and sedation (ASHP, 1999; Kovac, 2000; Jordan et al., 2005; Ison 
and Peroutka, 1986).  
1.4.1.11.3     Corticosteroids    
 Their mechanism of action as antiemetic is still unclear and not fully understood but 
are considered as safe and effective antiemetic. They exert their effect through prostaglandin 
antagonist or immunosuppressive effect. They act as a booster when use in combination with 
other antiemetic agents (e.g., metoclopramide and ondansetron) by increasing the emetic 
threshold. Dexamethasone has been vastly investigated and used for treatment of acute 
emesis. A dose of 8mg will be effective for moderately emetogenic chemotherapy and 20 mg 
is required for severely emetogenic chemotherapy (MASCC, 2004; The Italian Group for 
Antiemetic Research, 1998; The Italian Group for Antiemetic Research, 2004; Hesketh et 
al., 1994; Kovac, 2003; Jordan et al., 2005).  
1.4.1.11.4     Neurokinin-1-Receptor Antagonists 
 They represent a new class of antiemetic agents. Aprepitant penetrate through blood 
brain barrier and selectively block the NK-1 receptor. It has been approved by United State 
Federal and Drug Administration (FDA) as an effective oral antiemetic drug which is very 
effective in preventing acute and delayed emesis due to high emetogenic chemotherapy (e.g., 
cisplatin or cisplatin base therapy). Several studies had proven that aprepitant augmented the 
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action of dexamethasone and 5-HT3 combination in inhibiting acute and delayed emesis but 
specifically delayed emesis of highly emetogenic chemotherapy drugs. While for moderate 
emetogenic chemotherapy many studies showed that triple combination of aprepitant + 
dexamethasone + 5-HT3 receptor antagonist show superiority in the first 24 hours followed 
by aprepitant for the next 2 days alone. MASCC and NCCN guidelines both indicated the 
effectiveness of aprepitant plus 5-HT3 plus dexamethasone for the treatment of moderate 
chemotherapeutics drugs. The appropriate doses of aprepitant with acceptable side effects 
are 125 mg orally (p.o.) on day one and 80 mg (p.o.) on day 2 and 3. Since aprepitant is 
metabolized by CYP3A4 then dexamethasone dose must be reduced to about 50% when 
aprepitant is co administered in order to overcome any drug interaction (Jordan et al., 2005; 
Poli-Bigelli et al., 2003; Herrstedt, 2005). 
1.4.1.11.5     Cannabinoids   
 The usefulness of cannabinoids is limited because of their major toxic effects like 
dizziness, hallucination and dysphoria. Dysphoria specifically happens among older cancer 
patients who actually represent the largest proportion of cancer patients. These agents 
produce their antiemetic effect by acting directly on cannabinoids receptors found in the 
brain stem. Even so these agents are considered slightly better effective than conventional 
antiemetics agents such as metoclopramide, haloperidol and clopramide. These agents are 
more useful to be used in younger patients rather than in older cancer patients because they 
cause less euphoric and dysphoric side effects. Doses in the range of 5-10 mg/ m2, every 3-4 
hours orally will give the useful effect (Frytak et al., 1979; Jordan et al., 2005; Grunberg and 
Dugan, 2005; Mannix, 2004).                                
1.4.1.11.6     Benzodiazepines  
 They are usually used as an addition to antiemetic treatment to reduce anxiety due to 
chemotherapy treatment and the risk of anticipatory nausea and vomiting. Lorazepam is the 
preferred for anticipatory nausea and vomiting. Its anti-anxiety and sedative effect is very 
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useful when added to combination of antiemetic treatments, but its use as a single antiemetic 
is limited. Dose for Lorazepam usually is 1 to 2 mg every 6 hours for I.V. and 1 to 2 mg 
every 6 hours for oral administration (Jordan et al., 2005; Kris et al., 1985; Kris et al., 1987).  
1.4.1.12        Antiemetic guidelines for Acute and Delayed Chemotherapy   
                     Induced Nausea and Vomiting 
 
      The main guidelines used for the treatment of acute and delayed nausea and vomiting 
is shown in Table 2 below.  
  Table 1.2: Antiemetic Guideline for Acute and Delayed Nausea and Vomiting  
Degree of Emetogenicity Acute Emesis 
(Day 1) 
Delayed Emesis 
(days 2-5) 
High Dex+NK1+5-HT3 Dex+NK1 
Moderate Dex+NK1+5-HT3 or 
Dex+5-HT3 
Dex alone or 5-HT3 alone 
or metoclopramide alone or 
Dex+NK1 
Low Dex Non 
Minimal Non Non 
  5-HT3= 5-HT3 receptor antagonist, Dex= dexamethasone, NK1= neurokinin receptor 
antagonist(MASCC, 2004; Grunberg and Dugan, 2005; Morrow, 1985).   
 
1.4.1.13        Nausea and Vomiting in Breast Cancer 
 Breast cancer is considered as the most common type of cancer among women and is 
the highest type of cancer in United Kingdom. It comprised 30.4% of all the cases of cancer 
occurrence in Malaysia in 2002. It was reported that 200,000 new cases were diagnosed in 
each year and about 46,000 women die because of breast cancer in United State of America 
(USA) each year (Chang and Lo, 2003; Jones et al., 2007; Rhodes and McDaniel, 2001; 
Brookes et al., 2007). 
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Metastasis is one of the main characteristic of breast cancer in advanced stages. About 50% 
of the cases have the ability to metastasis to different organs mainly to liver, stomach, colon, 
lung, brain, small bowel and skeleton. Metastasis to the stomach and brain may occur after 
several years from the first chemotherapeutic treatment i.e., when the breast cancer became 
the advanced stage (between 2 to 5 years following its diagnosis). The metastasis to the brain 
will cause several problems and the most important are gut disturbance, headache, seizure, 
nausea and vomiting. While the metastasis of the advanced breast cancer to the stomach will 
lead to the incidence of stomach cancer which could then lead to several gastrointestinal 
problems such as delay in gastric emptying and bowel obstruction. All these effects lead to 
nausea and vomiting (Chang and Lo, 2003; Jones et al., 2007; Rhodes and McDaniel, 2001; 
Brookes et al., 2007). About 60 to 75% of patients who have advanced stages of breast 
cancer also suffer from bone metastasis leading to incidence of hypercalcemia which would 
cause nausea and vomiting (Lipton, 2003).   
Most of the chemotherapeutics agents used for treatment of breast cancer have an 
emetogenic potential that ranged between low (e.g., 5-flurouracil and gemcitabine) to 
moderate (e.g., cyclophosphamide and anthracyclines). Despite the physician having several 
effective and adequate antiemetic agents (5-HT3 and NK-1 receptors antagonists) in 
preventing nausea and vomiting, nevertheless significant proportion of breast cancer patients 
still suffer from nausea and vomiting after chemotherapy (Booth et al., 2007; Choi et al., 
2005; O' Shaughnessy, 2003; Hesketh, 2005). There are so many studies which focused on 
nausea and vomiting but very few of them are prospective observational studies in breast 
cancer exclusively that looked for the main risk factors associated with nausea and vomiting 
(Hesketh, 2005; Osoba, 2005).  
Besides that, there are many studies looking at the effect of nausea and vomiting associated 
with chemotherapy use on patients quality of life but there are few if any that investigated 
the effect of nausea and vomiting associated with solid cancer stages on patients quality of 
life (Hesketh, 2005; Rhodes and McDaniel, 2001). Choi et al. (2005) indicated that the 
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adjuvant chemotherapy {cyclophosphamide + methotrexate + 5-flourouracil (CMF) and 
cyclophosphamide + epirubicin + 5-flourouracil (CEF)} used for breast cancer patients 
caused nausea and vomiting. Anthracyclines is one of the most common agents used for 
breast cancer treatment but their clinical uses are limited due to acute nausea and vomiting, 
alopecia, neutropenia, anemia and thrombocytopenia. So many of these breast cancer 
patients showed severe nausea and vomiting which lead to a decrease in about 50% of the 
chemotherapy doses especially those who were treated with cyclophosphamide + 
methotrexate + 5- fluorouracil (CMF). Also due to the nausea and vomiting a high 
percentage of the breast cancer  patients contemplate of stopping the chemotherapy (Booth et 
al., 2007; Choi et al., 2005; O' Shaughnessy, 2003; Hesketh, 2005).   
1.4.1.14        Ethnic Variation Role in Incidence of Nausea and Vomiting  
Interindividual diversity in drug metabolism is caused by many factors including 
environmental factors, cultural factors related with type of diet, concomitant drug therapy as 
well as genetic factors i.e., ethnic variation. All of these variations play an important role in 
changing pharmacokinetic and pharmacodynamic properties, volume of distribution, 
elimination, disposition and clinical effect for many drugs (Gross et al., 1999; Ruzilawati et 
al., 2007). Much of this distinction has shown to be caused by alteration of the human 
cytochrome P450 enzymes (CYP) (Ruzilawati et al., 2007). CYP is the most vital enzymatic 
system concerned with drug metabolism. Approximately 65% of common drugs used are 
metabolized by cytochrome P450 enzymes and half of them are mediated by the CYP3A 
subfamily (Ruzilawati et al., 2007). The CYP3A subfamily consists of 4 members: CYP3A4, 
CYP3A5, CYP3A7 and CYP3A47 and represents about 30% of the total CYP in the human 
liver. The most superior subfamily among the 4 types that play the major role in metabolism 
of more than 60% of all drugs used in human is CYP3A4 (Ruzilawati et al., 2007). 
Miscellaneous CYP3A4 alleles in the population may partake in interindividual variability in 
CYP3A4 activity (Ruzilawati et al., 2007). In case of cancer patients nausea and vomiting 
can be clinically significant and severely incapacitating side effects of cytotoxic 
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chemotherapy (Aapro, 2004). These symptoms can symbolize a major therapeutic challenge 
and if unsatisfactorily controlled by antiemetic treatment, will limit a patient’s ability or 
desire to eat and drink, considerably reduce quality of life, threaten the success of therapy, 
and result in increased mortality, morbidity, and prominently health care costs (Aapro, 
2004). The management of nausea and vomiting has enhanced greatly in recent years, with 
the utilization of 5-HT3 (serotonin3)-receptor antagonists (Bloechl-Daum et al., 2006). 
These agents in combination with corticosteroids have been instrumental in improving the 
control of vomiting among patients receiving chemotherapy (Bloechl-Daum et al., 2006). All 
5-HT3 receptor antagonists are metabolized by the cytochrome P-450 enzymes: tropisetron 
and dolasetron  predominantly by CYP2D6, ondansetron partially by CYP2D6 but also by 
CYP3A4, CYP2E1, or CYP1A2, and granisetron mainly by CYP3A4 (Kaiser et al., 2002). 
Even so there is significant percentage of cancer patients who do not respond well to 5-HT3 
receptor antagonists. The most important cause for such individual variation in drug response 
may be differentiation in drug biotransformation by genetically polymorphic enzymes, such 
as the hepatic cytochrome P-450 enzyme subfamily (Kaiser et al., 2002). 
Granisetron is an influential and highly selective 5-HT3- receptor antagonist that has 
little or no attraction for other 5-HT receptors, or dopaminergic, adrenergic, benzodiazepine, 
histaminic, or opioid receptors. In contrast, other 5-HT3- receptor antagonists have affinities 
for divers receptor-binding sites (Bloechl-Daum et al., 2006). For example, ondansetron has 
obvious binding to 5-HT1B, 5-HT1C and μ-opioid receptor sites. Although not proven, the 
binding of these agents to extra receptor subtypes other than their target receptor may lie 
beneath the inferior adverse-event profile seen with ondansetron compared with granisetron 
(Bloechl-Daum et al., 2006). 
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1.4.1.15    Literature Review for Nausea and Vomiting          
   
 Warr mentioned in his study that both nausea and vomiting are the major problems 
that more than half of the cancer patients population will suffer from, either by the effect of 
cancer disease itself or chemotherapy. He mentioned that because of the closeness between 
nausea and vomiting many of the cancer patients express them as one symptom. Also Warr 
mentioned that some times one symptom will occur or take place without the other like for 
mild to moderate nausea it will not be accompanied by retching or vomiting. While patients 
with brain metastases and esophageal obstruction suffer from vomiting without preceding 
nausea. Warr showed that the physiology of nausea is still not clear and thus the prevention 
of vomiting is much easier than nausea. In his study he mentioned that nausea and vomiting 
occur in cancer patients either because of the cancer itself or because of the chemotherapy. 
But when cancer is the main cause this will required many investigations such as careful 
history, laboratory tests and physical examination in order to determine the underlining 
causes for nausea and vomiting with cancer so as to treat them correctly. Before 1980s a very 
high percentage of cancer patients treated with cisplatin or doxorubicin suffered from nausea 
and vomiting but the discovery and use of 5-HT3 receptor antagonist with corticosteroids in 
1990, had somewhat solved and prevent the occurrence of nausea and vomiting. However till 
now nausea and vomiting is still considered as a serious problem (Warr, 2008).    
          While Antonarakis and Hain (2004) described the effect of the chemotherapeutics 
drugs on the body cells is very harsh and thus the body will expel them as soon as possible 
by inducing nausea and vomiting. They also described nausea and vomiting as the most 
intractable, unpleasant and disgusting side effect suffered by many cancer patients especially 
children. Thus this emphasized that there are many risk factors related with patients that play 
a major role in nausea and vomiting incidence and severity including being female, young 
age, anxiety, motion sickness and poor control with previous chemotherapy. They also 
reported that risk factors responsible for nausea and vomiting incidence and severity 
associated with chemotherapy itself, route of administration, schedule and rate of 
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administration and the most important factor is the intrinsic emetogenicity factor of the 
chemotherapy itself. Thus the chemotherapy drugs are classified according to their 
emetogenicity.  
 Jordan et al. (2005) discussed the use of 5-HT3 and dexamethasone and considered 
that their use since 1990s has lead to the control of acute (70%) and of delayed emesis (40%) 
among cancer patients treated with highly emetogenic chemotherapy. She and her colleagues 
also reported that NK1 receptor antagonist offered a very effective protection against nausea 
and vomiting especially the delayed phase. Apart from NK1 others antiemetic drugs are also 
available for protection against emesis.  
 It has been notice that there is a strong association between gender and occurrence of 
nausea and vomiting as gender is one of the risk factor for onset of both symptoms. Thus it 
has been reported that female is less responsive to antiemetic treatment than male and the 
main reason leading to the reduced antiemetic drug effect among female is the 
polymorphism of genes regulating the serotoninergic system. Another factor considered as a 
risk factor for nausea and vomiting is race whereby it was reported that the incidence of 
nausea and vomiting associated with chemotherapy use among Asian cancer patients is much 
higher than those African and Caucasian cancer patients (Klosterhalfen et al., 2005).  
 Age also play a role in the incidence and severity of nausea and vomiting since it has 
been found that nausea and vomiting occurrence and severity is more among the younger 
patients as compared to the older patients (age > 50 years old). Other risk factors associated 
with incidence and severity of nausea and vomiting are prior history of nausea and vomiting 
with chemotherapy and alcohol consumption. The incidence and severity were reported to be 
more in patients with uncontrolled nausea and vomiting history and among patients who do 
not drink alcohol (Cancer care Nova Scotia, 2004/ www.cancercare.ns.ca/).       
 A pilot study by Grote et al. 2006 in 5 oncology centers in USA involving a total 
numbers of 58 cancer patients reported that 47% of them were women with breast cancer and 
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52% were treated with cyclophosphamide based chemotherapy. The main objective of their 
study was to evaluate the efficacy of 5-HT3 receptor antagonist i.e., palonosetron plus 
dexamethasone and aprepitant. The main results of this pilot study were that the main 
response towards this antiemetic combination was great. The proportion of those with no 
vomiting during the acute phase (0-24 hours) was 88%, while for those with delayed 
response (> 24-120 hours) was 78%. Also reported that 90% of the patients have no 
vomiting during the whole time interval and between 57% to 71% of the patients did not 
vomit during the 5 days post chemotherapy period. There were also no nausea incidence. So 
the main conclusion Grote and his colleagues reached was that the combination of antiemetic 
treatment for the prevention of both nausea and vomiting of moderate chemotherapy 
treatment was good and effective.  
 Booth et al., (2007) made a prospective study on 143 breast cancer patients in Canada 
and reported that most of them (91%) suffered from early stages of breast cancer. The mean 
age of the patients was 51.4 years that ranged from 24 to 76 years. The patients received 766 
cycles of chemotherapy (range 1-6 cycles; median= 3 cycles) and the main chemotherapy 
used was anthracyclines. Booth and his colleagues mentioned that the chemotherapy used in 
breast cancer treatment were either low emetogenic chemotherapy (taxanes, gemcitabine and 
5-flourouracil) or moderate emetogenic chemotherapy (cyclophosphamide and 
anthracyclines). In the first 24 hours, very few patients (10%) showed severe (i.e., grade 4) 
nausea and vomiting, but in the delay phase 70% of the patients developed grade 1 - 3 
nausea. Unlike most studies, this prospective study focused on all the 6 cycles of 
chemotherapy and reported that the prevalence of nausea and vomiting was insignificantly 
affected by multiply cycles of chemotherapy. The differences in the grades of nausea and 
vomiting either acute or delayed associated with chemotherapy happened within the first 
cycle. In their study it was also observed that very few patients suffered from severe nausea 
and vomiting (i.e., < 10%). This could be because most of the patients were at the early stage 
of breast cancer and were treated with anthracyclines chemotherapy which has moderate 
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emetogenic potential and also they were treated with an effective antiemetic treatment (NK-1 
antagonist). The major symptom observed in this study was delayed nausea (70%) which 
emphasized the difficulty to control such symptom as compared to vomiting. 
 Bloechl-Daum et al. (2006) accomplished a prospective, multicenter and multinational 
study in Denmark on 298 cancer patients treated with highly emetogenic chemotherapy 
(HEC) and moderately emetogenic chemotherapy (MEC). They suffered from different types 
of cancer but breast and lung cancer were the most common type. The main objective for this 
study was to determine the impact of CINV on patients QOL. Data collection process was 
done by using functional living index- emesis (FLIE) questionnaire. The main results of this 
study was that CINV continue to adversely effects cancer patients QOL, especially nausea 
which has a greater negative impact on QOL than vomiting. This study mentioned that it is 
very important to find or develop a new antiemetic regimen and suggested that studies 
should investigate and examine the effectiveness of new antiemetic guideline by ASCO in 
reducing or preventing the negative impact of CINV on cancer patients QOL.  
 Cohen et al. (2007) conducted a study in California, USA on 151 cancer patients. 
Fifty-five percent of them were breast cancer patients followed by patients with lymphoma, 
lung and other different types of cancer. The patients were from different races and ethnicity. 
The main objectives of their study were to determine the prevalence of acute and delayed 
nausea and vomiting caused by chemotherapy treatment and to evaluate their effect on 
patients. The data were collected from cancer patients who were scheduled for the first cycle 
of new chemotherapy regimen and the occurrence of CINV were recorded by completing a 
daily dairy and the Functional Living Index-Emesis (FLIE tool). The main result was that 
CINV has a direct effect on cancer patients QOL. 
 The main differences between these two studies and present study is that they were 
just looking for the negative impact of CINV on cancer patients QOL with different types of 
chemotherapy regimens and different types of cancer but did not look at the main risks 
factors for nausea and vomiting onset and severity which was performed in our study. 
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Besides that present study will also try to find the main impact of delayed CINV on breast 
cancer QOL. Also the FLIE questionnaire employed by the researchers only focused on the 
assessment of cancer patients QOL, but not related with the effectiveness of antiemetic 
treatments. While present study will be focusing on specific type of solid cancer, specific 
chemotherapy regimens, main risk factors for nausea and vomiting onset and severity, 
effectiveness of the antiemetic treatments and on the main impact of CINV i.e., acute and 
delay on cancer patients QOL. This present study also used a mix questionnaire of MANE 
and ONEM to look for the two main parameters which are the effectiveness of antiemetic 
treatment and the impact on QOL. According to the World Health Organization (WHO), the 
definitive goal for palliative care is the achievement of the best QOL for cancer patients 
which could be accomplish by distinguishing the main risk factors, proper treatment and 
symptoms (Beijer et al., 2008) which are the main emphasis of present study.    
          Glaus et al. (2004) also conducted a prospective cross-sectional study on 249 cancer 
patients from several centers in Spain, Germany, Austria and Switzerland. The main aim of 
their study was to evaluate the incidence of moderate to severe emetogenic chemotherapy 
induce nausea and vomiting and their effect on patients daily life activities. About 78% of 
the patients were women, with a mean age of 54 years old. Breast, lung and ovarian cancers 
were the most predominant cancer and each patient was treated with 2.0 types of 
chemotherapy agents and 2.5 types of antiemetic drugs. The main results were that delayed 
emesis was the highest in incidence (38%) as compared to acute emesis. Even in those 
patients treated with adequate antiemetic treatment delayed emesis incidence was still high. 
The main explanation given was patients were not treated optimally for delayed emesis or 
may be because they were treated with cyclophosphamide. Another explanation given was 
that the neurological control for delayed and acute emesis are distinctly different from each 
other, and therefore the main control of risk factor for delayed emesis incidence is still 
unclear. 
